Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Diagnostic Accuracy of a Novel and Rapid Lipoarabinomannan Test for Diagnosing Tuberculosis Among People With Human Immunodeficiency Virus

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. High Carriage Rates of Multidrug-Resistant Gram-Negative Bacteria in Neonatal Intensive Care Units From Ghana

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Extrapulmonary Tuberculosis in Denmark From 2009 to 2014; Characteristics and Predictors for Treatment Outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Oxacillinase-181 Carbapenemase-Producing Klebsiella pneumoniae in Neonatal Intensive Care Unit, Ghana, 2017-2019

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Remdesivir til behandling af COVID-19-pneumoni

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Stephanie Bjerrum
  • Tobias Broger
  • Rita Székely
  • Satoshi Mitarai
  • Japheth A Opintan
  • Ernest Kenu
  • Margaret Lartey
  • Kennedy K Addo
  • Kinuyo Chikamatsu
  • Aurélien Macé
  • Samuel G Schumacher
  • Emmanuel Moreau
  • Maunank Shah
  • Isik Somuncu Johansen
  • Claudia M Denkinger
View graph of relations

Background: The novel Fujifilm SILVAMP TB-LAM (FujiLAM) assay detects mycobacterial lipoarabinomannan in urine and has demonstrated superior sensitivity to the Alere Determine TB-LAM Ag (AlereLAM) assay for detection of tuberculosis among hospitalized people with human immunodeficiency virus (PWH). This is the first study to evaluate the assay among a broad population referred for antiretroviral therapy including both outpatients (mainly) and inpatients.

Methods: We assessed diagnostic accuracy of FujiLAM and AlereLAM assays in biobanked urine samples from a cohort of adults referred for antiretroviral therapy in Ghana against a microbiological and a composite (including clinical judgement) reference standard, and we assessed the association of FujiLAM test positivity with mortality.

Results: We evaluated urine samples from 532 PWH (462 outpatients, 70 inpatients). Against a microbiological reference standard, the sensitivity of FujiLAM was 74.2% (95% confidence interval [CI], 62.0-84.2) compared to 53.0% (95% CI, 40.3-65.4) for AlereLAM, a difference of 21.2% (CI, 13.1-32.5). Specificity was 89.3% (95% CI, 85.8-92.2) versus 95.6% (95% CI, 93.0-97.4) for FujiLAM and AlereLAM, a difference of -6.3% (95% CI -9.6 to -3.3). Specificity estimates for FujiLAM increased markedly to 98.8% (95% CI, 96.6-99.8) in patients with CD4 >100 cells/µL and when using a composite reference standard. FujiLAM test positivity was associated with increased cumulative risk of mortality at 6 months (hazard ratio, 4.80; 95% CI, 3.01-7.64).

Conclusions: FujiLAM offers significantly increased diagnostic sensitivity in comparison to AlereLAM. Specificity estimates for FujiLAM were lower than for AlereLAM but were affected by the limited ability of the reference standard to correctly diagnose tuberculosis in individuals with low CD4 counts.

Original languageEnglish
JournalOpen Forum Infectious Diseases
Volume7
Issue number1
Pages (from-to)ofz530
ISSN2328-8957
DOIs
Publication statusPublished - Jan 2020

ID: 62370687